An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.
Video content above is prompted by the following questions:
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More